Orthopedics This Week - 2018 | July 17, 2018

ORTHOPEDICS THIS WEEK VOLUME 14, ISSUE 23 | JULY 17, 2018 rior to allografts especially in younger patients, more accessible. Hamstring and patella tendon grafts up until now have been the only autograft options and they are not a good fit for all patients. Hamstrings sometimes are too small for pediatric patients and the patella tendon autograft can interrupt growth plates. Missouri Osteochondral Preservative MOPS – MTF Biologics in conjunction with Missouri Orthopedic Institute & ConMed Inventors: James L. Cook, DVM, PhD, OTSC, Aaron M. Stoker, M.S., Ph.D., Clark T. Hung, PhD., Eric Lima, Ph.D. Engineers: Clark T. Hung, Ph.D., Eric Lima, Ph.D. Longer chondrocyte viability in an osteochondral implants from MTF Foundation—the most trusted allograft supplier—was a no-brainer for this year’s best technology in sports medi- cine award. Named “The Missouri Osteochon- dral Preservation System (MOPS SM )” because of the close partnership with the University of Missouri, this inno- vative allograft was designed by MTF’s engineers to more completely preserve donated cartilage, bone, meniscus, liga- ment and intervertebral disc during the required disease testing period and the storage period before transplantation, which is typically up to 70 days from procurement. This novel method, which complies with FDA Regulation 21 CFR Part 1271, Human Cells, Tissues, Cellular and Tissue Based Products (HCT/Ps), offers many more benefits than cur- rent preservation systems including the use of closed containers, serum- free media that includes dexametha- sone, and the ability to be stored at room temperature. This system extends chondrocyte viability which usually falls below essential levels within 28 days after procurement with current tissue bank preservation protocols. The Missouri Osteochondral Preservation System (MOPS) has been validated to maintain essential chondrocyte viability, articular cartilage extracellular matrix composi- tion, and material properties in all grafts for at least 56 days after procurement. It is not regulated as a medical device. Right to left: Greg Whitleigh, Michael Nasert, Marc Jacobs, James Stanndard, M.D., Matt Citro, John Lerch Fresh osteochondral allografts are in limited sup- ply. Longer preservation times with the Missouri Osteochondral Preservation System means more allografts will be available when need- ed. These allografts have also been associated with lower total complication rates (p = .044) compared to standard- of-care grafts. 10 ClearEdge Brain Health Tool- kit – Quadrant Biosciences Inc. Quadrant BioScience has developed a way to monitor brain health after a con- cussion through functional assessment! The system, called ClearEdge Brain Health Toolkit, was developed in coop- eration with researchers and clinicians at SUNY Upstate Medical. The toolkit is a collection of FDA- cleared and listed functional assess- ment tools to track subtle changes in cognitive function, balance and patient symptoms that can occur over time after a concussion. Similar to heart and kid- ney function tests, the ClearEdge Brain Health Toolkit uses functional markers Right to left: CEO Richard Uhlig, David MacLean, Chrys Chrysanthou ClearEdge Brain Health Toolkit ryortho.com | 1-888-352-1952

Orthopedics This Week - 2018 | July 17, 2018 | Page 10